NCT02687490: Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer

NCT02687490
Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 70 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic unstable central nervous system (CNS) metastases that require treatment- see trial for details
https://ClinicalTrials.gov/show/NCT02687490

Comments are closed.

Up ↑